These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8463521)

  • 1. L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results.
    Burke WJ; Ranno AE; Roccaforte WH; Wengel SP; Bayer BL; Willcockson NK
    J Am Geriatr Soc; 1993 Apr; 41(4):367-70. PubMed ID: 8463521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial.
    Burke WJ; Roccaforte WH; Wengel SP; Bayer BL; Ranno AE; Willcockson NK
    J Am Geriatr Soc; 1993 Nov; 41(11):1219-25. PubMed ID: 8227897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-deprenyl in Alzheimer's disease: cognitive and behavioral effects.
    Freedman M; Rewilak D; Xerri T; Cohen S; Gordon AS; Shandling M; Logan AG
    Neurology; 1998 Mar; 50(3):660-8. PubMed ID: 9521253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition.
    Tariot PN; Cohen RM; Sunderland T; Newhouse PA; Yount D; Mellow AM; Weingartner H; Mueller EA; Murphy DL
    Arch Gen Psychiatry; 1987 May; 44(5):427-33. PubMed ID: 3107514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.
    Mangoni A; Grassi MP; Frattola L; Piolti R; Bassi S; Motta A; Marcone A; Smirne S
    Eur Neurol; 1991; 31(2):100-7. PubMed ID: 1904354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study of low-dose L-deprenyl in Alzheimer's disease.
    Schneider LS; Pollock VE; Zemansky MF; Gleason RP; Palmer R; Sloane RB
    J Geriatr Psychiatry Neurol; 1991; 4(3):143-8. PubMed ID: 1953966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia.
    Piccinin GL; Finali G; Piccirilli M
    Clin Neuropharmacol; 1990 Apr; 13(2):147-63. PubMed ID: 2109658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-deprenyl therapy improves verbal memory in amnesic Alzheimer patients.
    Finali G; Piccirilli M; Oliani C; Piccinin GL
    Clin Neuropharmacol; 1991 Dec; 14(6):523-36. PubMed ID: 1773423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selegiline in the treatment of behavioural disturbance in Alzheimer's disease.
    Lawlor BA; Aisen PS; Green C; Fine E; Schmeïdler J
    Int J Geriatr Psychiatry; 1997 Mar; 12(3):319-22. PubMed ID: 9152715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl.
    Martignoni E; Bono G; Blandini F; Sinforiani E; Merlo P; Nappi G
    J Neural Transm Park Dis Dement Sect; 1991; 3(1):15-25. PubMed ID: 1712206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type.
    Tariot PN; Goldstein B; Podgorski CA; Cox C; Frambes N
    Am J Geriatr Psychiatry; 1998; 6(2):145-54. PubMed ID: 9581210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive effects of L-deprenyl in Alzheimer's disease.
    Tariot PN; Sunderland T; Weingartner H; Murphy DL; Welkowitz JA; Thompson K; Cohen RM
    Psychopharmacology (Berl); 1987; 91(4):489-95. PubMed ID: 3108930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study.
    Agnoli A; Fabbrini G; Fioravanti M; Martucci N
    Eur Neuropsychopharmacol; 1992 Mar; 2(1):31-5. PubMed ID: 1638171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
    Schneider LS; Olin JT; Pawluczyk S
    Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tranylcypromine compared with L-deprenyl in Alzheimer's disease.
    Tariot PN; Sunderland T; Cohen RM; Newhouse PA; Mueller EA; Murphy DL
    J Clin Psychopharmacol; 1988 Feb; 8(1):23-7. PubMed ID: 3127432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-deprenyl and physostigmine for the treatment of Alzheimer's disease.
    Marin DB; Bierer LM; Lawlor BA; Ryan TM; Jacobson R; Schmeidler J; Mohs RC; Davis KL
    Psychiatry Res; 1995 Oct; 58(3):181-9. PubMed ID: 8570774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary communication. A double-blind placebo-controlled trial of L-tryptophan to assess the degree of cognitive and behavioural improvement in patients with Alzheimer-type dementia and to compare differential response in clinical sub-groups.
    Bentham PW
    Int Clin Psychopharmacol; 1990 Oct; 5(4):261-72. PubMed ID: 2081897
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of selegiline (deprenyl) on cognition in early Parkinson's disease.
    Dalrymple-Alford JC; Jamieson CF; Donaldson IM
    Clin Neuropharmacol; 1995 Aug; 18(4):348-59. PubMed ID: 8665548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.